Cipla’s New Move in Diabetes Segment with Eli Lilly’s Tirzepatide Launch

Cipla Ltd has announced a partnership with Eli Lilly and Company (India) Private Ltd to distribute and promote tirzepatide in India under the brand name Yurpeak. This collaboration marks a significant step in the expansion of advanced diabetes care in the country, as Yurpeak becomes the second brand of tirzepatide to be launched in India. 

The agreement allows Cipla to distribute and promote the medicine while Lilly continues to manufacture and supply it. The pricing for Yurpeak will remain consistent with Lilly’s existing brand, Mounjaro, launched earlier in March 2025.

Strategic Collaboration to Improve Access

According to Winselow Tucker, President and General Manager of Lilly India, this partnership reflects Lilly’s focus on improving access to innovative treatments for chronic conditions such as diabetes and obesity. 

He highlighted that introducing a second brand through a commercial agreement with Cipla aligns with the company’s mission of enhancing access to advanced medicines across diverse communities. This collaboration will extend the reach of tirzepatide beyond key urban areas, ensuring more patients can benefit from this treatment.

Cipla’s Entry into Obesity and Diabetes Care

Achin Gupta, Global Chief Operating Officer of Cipla Ltd, stated that the introduction of Yurpeak (tirzepatide) represents the company’s entry into the obesity care segment. He noted that Cipla’s focus remains on advancing patient care through access to global scientific innovations. 

The partnership underscores Cipla’s commitment to addressing chronic health conditions with the same scale and dedication that have shaped its leadership in respiratory and other long-term therapies.

About Tirzepatide and Its Benefits

Tirzepatide is a prescription medicine used as an adjunct to diet and exercise for managing type 2 diabetes and for chronic weight management in adults with obesity (BMI ≥ 30) or those overweight (BMI ≥ 27) with at least one related health condition. 

It works as a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Yurpeak will be offered in the KwikPen format, a single-patient-use prefilled pen with six available dose strengths, allowing healthcare professionals to tailor treatment plans effectively.

Cipla Share Price Performance

As of October 23, 2025, 4:01 PM, Cipla share price stood at ₹1,645, down 1.12%, with a market capitalisation of ₹1,32,898 crore. The stock has shown steady movement, with a 52-week high of ₹1,669 and a low of ₹1,310. 

Cipla’s P/E ratio of 24.6, ROCE of 22.7%, and ROE of 17.8% reflect a stable position in the pharmaceutical sector, highlighting investor confidence in its growth strategies.

Read More:Umang Vohra to Step Down as Cipla CEO by March 2026

Conclusion

Cipla’s partnership with Lilly marks a noteworthy development in India’s healthcare sector, expanding the availability of advanced diabetes and obesity treatments. The introduction of Yurpeak demonstrates Cipla’s continued focus on enhancing patient access to innovative therapies while maintaining strong financial and operational performance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.